The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Perioperative COX2 and β‐adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial
Abstract
Background: Preclinical studies have implicated excess release of catecholamines and prostaglandins in the mediation of prometastatic processes during surgical treatment of cancer. In this study, we tested the combined perioperative blockade of these pathways in patients with colorectal cancer (CRC). Methods: In a randomized, double‐blind, placebo‐controlled biomarker trial involving 34 patients, the β‐blocker propranolol and the COX2‐inhibitor etodolac were administered for 20 perioperative days, starting 5 days before surgery. Excised tumors were subjected to whole genome messenger RNA profiling and transcriptional control pathway analyses. Results: Drugs were well‐tolerated, with minor complications in both the treatment group and the placebo group. Treatment resulted in a significant improvement ( P < .05) of tumor molecular markers of malignant and metastatic potential, including 1) reduced epithelial‐to‐mesenchymal transition, 2) reduced tumor infiltrating CD14 + monocytes and CD19 + B cells, and 3) increased tumor infiltrating CD56 + natural killer cells. Transcriptional activity analyses indicated a favorable drug impact on 12 of 19 a priori hypothesized CRC‐related transcription factors, including the GATA, STAT, and EGR families as well as the CREB family that mediates the gene regulatory impact of β‐adrenergic– and prostaglandin‐signaling. Alterations observed in these transcriptional activities were previously associated with improved long‐term clinical outcomes. Three‐year recurrence rates were assessed for long‐term safety analyses. An intent‐to‐treat analysis revealed that recurrence rates were 12.5% (2/16) in the treatment group and 33.3% (6/18) in the placebo group ( P = .239), and in protocol‐compliant patients, recurrence rates were 0% (0/11) in the treatment group and 29.4% (5/17) in the placebo group ( P = .054). Conclusions: The favorable biomarker impacts and clinical outcomes provide a rationale for future randomized placebo‐controlled trials in larger samples to assess the effects of perioperative propranolol/etodolac treatment on oncological clinical outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a similar trial by Haldar et al., in 34 patients with colorectal cancer there was also a markedly reduction of recurrences in the treatment group with propranolol and etodolac (12.5%) compared to the placebo group (33.3%) [22].”
From Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial (2025) · cites this paper as [22]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,985
Steptoe, A., Hamer, M., & Chida, Y. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.03.011 · Cited by 1,278
Sympathetic nervous system regulation of the tumour microenvironment
Cole, S. W., Nagaraja, A. S., Lutgendorf, S. K., Green, P. A., & Sood, A. K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3978 · Cited by 576
Self-citationPerioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556
Exploiting the critical perioperative period to improve long-term cancer outcomes
Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487
Self-citationQuantitative evidence for early metastatic seeding in colorectal cancer
Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J. A., Shaffer, J. S., Suarez, C. J., Berghoff, A. S., Cremolini, C., Falcone, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0423-x · Cited by 480
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
Reinert, T., Schøler, L. V., Thomsen, R., Tobiasen, H., Vang, S., Nordentoft, I., Lamy, P., Kannerup, A.-S., Mortensen, F. V., Stribolt, K., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308859 · Cited by 467
COX-2: A Molecular Target for Colorectal Cancer Prevention
Brown, J. R., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.051 · Cited by 444
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer
Erreni, M., Mantovani, A., & Allavena, P. (2010) · Cancer Microenvironment · doi:10.1007/s12307-010-0052-5 · Cited by 336
Macrophages as Key Drivers of Cancer Progression and Metastasis
Nielsen, S. R., & Schmid, M. C. (2017) · Mediators of Inflammation · doi:10.1155/2017/9624760 · Cited by 308
Buvanendran, A., Kroin, J. S., Berger, R. A., Hallab, N. J., Saha, C., Negrescu, C., Moric, M. M., Caicedo, M. S., & Tuman, K. J. (2006) · Anesthesiology · doi:10.1097/00000542-200603000-00005 · Cited by 290
Shaashua, L., Shabat-Simon, M., Haldar, R., Matzner, P., Zmora, O., Shabtai, M., Sharon, E., Allweis, T. M., Barshack, I., Hayman, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0152 · Cited by 289
Self-citationBenish, M., Bartal, I., Goldfarb, Y., Levi, B., Avraham, R., Raz, A., & Ben-Eliyahu, S. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9890-5 · Cited by 281
Self-citationTumor Budding is a Strong and Reproducible Prognostic Marker in T3N0 Colorectal Cancer
Wang, L. M., Kevans, D., Mulcahy, H. E., O'Sullivan, J. N., Fennelly, D. W., Hyland, J. M., O’Donoghue, D. P., & Sheahan, K. D. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318184cd55 · Cited by 280
Improving Postoperative Immune Status and Resistance to Cancer Metastasis
Goldfarb, Y., Sorski, L., Benish, M., Levi, B. Z., Melamed, R., & Ben‐Eliyahu, S. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e318211d7b5 · Cited by 262
Self-citationHost Factors and Cancer Progression: Biobehavioral Signaling Pathways and Interventions
Lutgendorf, S. K., Sood, A. K., & Antoni, M. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9357 · Cited by 249
Reversal of Tumor-Induced Immunosuppression: A New Approach to Cancer Therapy
Wojtowicz‐Praga, S. (1997) · Journal of Immunotherapy · doi:10.1097/00002371-199705000-00001 · Cited by 242
Glasner, A., Avraham, R., Rosenne, E., Benish, M., Zmora, O., Shemer, S., Meiboom, H., & Ben‐Eliyahu, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903301 · Cited by 239
Self-citationShah, S., Divekar, A., Hilchey, S. P., Cho, H.-M., Newman, C. L., Shin, S.-U., Nechushtan, H., Challita-Eid, P. M., Segal, B. M., Yi, K. H., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21177 · Cited by 227
Hiller, J. G., Cole, S. W., Crone, E. M., Byrne, D. J., Shackleford, D. M., Pang, J.-M. B., Henderson, M. A., Nightingale, S. S., Ho, K. M., Myles, P. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2641 · Cited by 223
Self-citationImmune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis
Menon, A. G., Rhijn, C. M. J., Morreau, H., Putter, H., Tollenaar, R. A. �. �., van de Velde, C. J. �., Fleuren, G. J., & Kuppen, P. J. K. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700055 · Cited by 216
Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set
O’Connell, M. J., Campbell, M. E., Goldberg, R. M., Grothey, A. F., Seitz, J. F., Benedetti, J., André, T., Haller, D. G., & Sargent, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8261 · Cited by 214
Májek, O., Gondos, Á., Jansen, L., Emrich, K., Holleczek, B., Katalinic, A., Nennecke, A., Eberle, A., Brenner, H., & the GEKID Cancer Survival Working Group (2013) · PLoS ONE · doi:10.1371/journal.pone.0068077 · Cited by 196
Expression-based monitoring of transcription factor activity: the TELiS database
Cole, S. W., Yan, W., Galic, Z., Arevalo, J., & Zack, J. A. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti038 · Cited by 185
Self-citationNeil, J. R., JOHNSON, K. M., Nemenoff, R. A., & Schiemann, W. P. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn202 · Cited by 159
Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer
Koo, J. H., & Leong, R. W. L. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05992.x · Cited by 141
Characterization of tumor-associated B-cell subsets in patients with colorectal cancer
Shimabukuro‐Vornhagen, A., Schlößer, H., Gryschok, L., Malcher, J., Wennhold, K., Garcia-Marquez, M. A., Herbold, T., Neuhaus, L. S., Becker, H., Fiedler, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1701 · Cited by 127
Neeman, E., Zmora, O., & Ben‐Eliyahu, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1087 · Cited by 113
Self-citationNatural killer cells infiltrating colorectal cancer and MHC class I expression
Sandel, M. H., Speetjens, F. M., Menon, A. G., Albertsson, P., Basse, P. H., Hokland, M., Nagelkerke, J. F., Tollenaar, R. A. E. M., van de Velde, C. J. �., & Kuppen, P. J. K. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.039 · Cited by 112
Armaiz-Peña, G. N., González-Villasana, V., Nagaraja, A. S., Rodriguez‐Aguayo, C., Sadaoui, N. C., Stone, R. L., Matsuo, K., Dalton, H. J., Previs, R. A., Jennings, N. B., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2887 · Cited by 105
Self-citationAugestad, K. M., Bakaki, P. M., Rose, J., Crawshaw, B. P., Lindsetmo, R. O., Dørum, L. M., Koroukian, S. M., & Delaney, C. P. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.07.009 · Cited by 102
Nakamura, T., Mitomi, H., Kikuchi, S., Ohtani, Y., & Sato, K. (2005) · PubMed · Cited by 92
Haldar, R., Shaashua, L., Lavon, H., Lyons, Y. A., Zmora, O., Sharon, E., Birnbaum, Y., Allweis, T. M., Sood, A. K., Barshack, I., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.05.014 · Cited by 88
Self-citationSorski, L., Melamed, R., Matzner, P., Lavon, H., Shaashua, L., Rosenne, E., & Ben-Eliyahu, S. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.05.017 · Cited by 85
Self-citationRicon, I., Hanalis‐Miller, T., Haldar, R., Jacoby, R., & Ben‐Eliyahu, S. (2019) · Cancer · doi:10.1002/cncr.31594 · Cited by 71
Self-citationDavis, F. M., Parsonage, M. T., Cabot, P. J., Parat, M., Thompson, E. W., Roberts‐Thomson, S. J., & Monteith, G. R. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-76 · Cited by 60
Adhim, Z., Matsuoka, T., Bito, T., Shigemura, K., Lee, K.-M., Kawabata, M., Fujisawa, M., Nibu, K., & Shirakawa, T. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.262 · Cited by 59
Norepinephrine induced epithelial–mesenchymal transition in HT-29 and A549 cells in vitro
Zhang, J., Deng, Y., Liu, J., Wang, Y., Yi, T., Huang, B., He, S., Zheng, B., & Jiang, Y. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2044-9 · Cited by 57
Knight, J. M., Rizzo, J. D., Hari, P., Pasquini, M. C., Giles, K. E., D’Souza, A., Logan, B. R., Hamadani, M., Chhabra, S., Dhakal, B., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000765 · Cited by 53
Self-citationBates, R. C., Pursell, B. M., & Mercurio, A. M. (2007) · Cells Tissues Organs · doi:10.1159/000101300 · Cited by 48
Jang, T. J., Jeon, K. H., & Jung, K. H. (2009) · Yonsei Medical Journal · doi:10.3349/ymj.2009.50.6.818 · Cited by 43
Knight, J. M., Kerswill, S. A., Hari, P., Cole, S. W., Logan, B. R., D’Souza, A., Shah, N. N., Horowitz, M. M., Stolley, M. R., Sloan, E. K., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4509-0 · Cited by 36
Self-citationHaldar, R., & Ben‐Eliyahu, S. (2018) · Future Oncology · doi:10.2217/fon-2017-0635 · Cited by 32
Self-citationDoes early metastatic seeding occur in colorectal cancer?
Magrì, A., & Bardelli, A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0200-4 · Cited by 18
Research works printed but not linked: 1
- Ferlay J, 2018, Global and Regional Estimates of the Incidence and Mortality for 38 Cancers: GLOBOCAN 2018
Cited by
Sorted by citations
Stress and cancer: mechanisms, significance and future directions
Eckerling, A., Ricon-Becker, I., Sorski, L., Sandbank, E., & Ben-Eliyahu, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00395-5 · Cited by 348
Self-citationRole of adrenergic receptor signalling in neuroimmune communication
Chhatar, S., & Lal, G. (2021) · Current Research in Immunology · doi:10.1016/j.crimmu.2021.11.001 · Cited by 143
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications
Pu, T., Sun, J., Ren, G., & Li, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02241-8 · Cited by 155
“515 Although propranolol has shown promising effects in improving the TIME in these clinical studies, the impact on tumor recurrence rates and long-term survival outcomes of patients requires further observation and investigation.”
Stress and cancer: The mechanisms of immune dysregulation and management
Liu, Y.-X., Tian, S., Ning, B., Huang, T., Li, Y., & Wei, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032294 · Cited by 137
Neurobiology of Cancer: The Role of β-Adrenergic Receptor Signaling in Various Tumor Environments
Mravec, B., Horváthová, Ľ., & Hunáková, Ľ. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217958 · Cited by 117
Metadata
- Authors
- Haldar, R., Ricon‐Becker, I., Radin, A., Gutman, M., Cole, S. W., Zmora, O., & Ben‐Eliyahu, S.
- Affiliations
- Tel Aviv University (IL)
- University of California, Los Angeles (US)
- Sheba Medical Center (IL)
- Assaf Harofeh Medical Center (IL)
- Corresponding author
- Ben‐Eliyahu, Shamgar
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2020-06-13
- Volume
- 126
- Issue
- 17
- Pages
- 3991-4001
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W3035075055
- Cited by
- 122
- References
- 47
- Citations by year
- 2026: 24 · 2025: 17 · 2024: 13 · 2023: 22 · 2022: 25 · 2021: 16 · 2020: 5
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Israel Science Foundation (1406/10)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, perioperative therapy, propranolol, etodolac, COX-2 inhibition, beta-adrenergic blockade, catecholamines, prostaglandins, metastasis, epithelial-mesenchymal transition, tumor-infiltrating immune cells, natural killer cells, CD14+ monocytes, CD19+ B cells, tumor recurrence, gene expression profiling, transcription factors, GATA, STAT, EGR, CREB
- MeSH terms
- Adrenergic beta-Antagonists, Adult, Aged, Female, Humans, Immunity, Innate, Inflammation, Killer Cells, Natural, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Biomarkers, Tumor, Colorectal Neoplasms, Signal Transduction, Cell Line, Tumor, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
